# Earnings Frenzy: Bulls Roar, Bears Struggle! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-02-28T15:00:00.204Z Source: https://newsyai.com/edition/30217a1d-c913-4e80-bec6-aae0af984860 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- # Earnings Apocalypse: Bulls Jizzing Fireworks, Bears Puking Bile on AI & Biotech Boners! Market's circle-jerking through AI Armageddon and tariff turds—Nasdaq puking another **0.3%** amid credit cramps, war whispers, and inflation boners. But earnings? Holy shitshow! Optics whores like **AAOI** exploding **+45%** on AI ramps, scrubs slut **FIGS** +**25%** on med margin magic, and vaccine vampire **NVAX** +**24%** swinging to profits. Analysts creaming upside calls, shorts shitting bricks (NVAX 32% shorted), dilution dick-slaps loom. Fresh bloodbaths post-SaaS slaughter—here's the **three** nuttiest nutfights: arguments unloaded, my raw first-principles ball-busting synthesis.[[1]](https://www.fool.com/investing/2026/02/16/ai-stock-just-wall-streets-most-controversial-pick)[[2]](https://finance.yahoo.com/news/why-novavax-nvax-stock-soaring-180433998.html)[[3]](https://www.investors.com/news/technology/aaoi-stock-applied-optoelectronics-earnings-aaoi-news-q42025) --- ## 1) Applied Optoelectronics (AAOI): “AI optics orgasm” vs “Dilution douchebag” **Why it’s loud** **AAOI** detonated **+44%** to **~$77** (intraday highs **$89**), smashing 52-week peaks after Q4 rev crush and AI-fueled guidance. Full-year rev records on data center/CATV demand, ramping new optical gear for Amazon hyperscalers. Analysts hoisting **$125** targets (Rosenblatt), but dilution from offerings haunts the high-beta bitch (**beta ~2.5**).[[3]](https://www.investors.com/news/technology/aaoi-stock-applied-optoelectronics-earnings-aaoi-news-q42025)[[4]](https://ca.investing.com/news/stock-market-news/applied-optoelectronics-stock-surges-45-on-q4-beat-guidance-93CH-4485794) **Bull case (datacenter datacenter datacenter)** Q4 beat + guidance tops estimates as AI fiber optics flywheel spins—Amazon deals printing, EBITDA margins juicing. "Ramps up for AI demand" amid Nvidia glow-up, Wall Street sees **60%+ upside** on Ethernet/AI accelerator boom.[[3]](https://www.investors.com/news/technology/aaoi-stock-applied-optoelectronics-earnings-aaoi-news-q42025)[[5]](https://simplywall.st/stocks/us/tech/nasdaq-aaoi/applied-optoelectronics/news/applied-optoelectronics-ramps-up-for-ai-demand-as-dilution-q) **Bear case (offering overdose)** Dilution dilution dilution—recent upsizes tanked sentiment before, volatile AF (YTD wild swings). Guidance froth ignores macro ad spend chills, competition from Coherent/Lumentum. High-beta = rotation rape fodder.[[5]](https://simplywall.st/stocks/us/tech/nasdaq-aaoi/applied-optoelectronics/news/applied-optoelectronics-ramps-up-for-ai-demand-as-dilution-q) **My take, first principles (passive optical monopoly vs cash burn circlejerk)** Core: AAOI's tunable lasers own 800G/1.6T AI datacenter plumbing (low power, high density = moat porn), Amazon ramp = recurring rev rocket. Dilution? Pragmatic for capex scale in cap-heavy optics. Bulls nut if Q1 pilots > expectations; bears feast on tariff tariffs. Buy the dip sub-$70 post-puke, **$90/$110 call spreads**—hedge that funding fuckery. Risk: China export bans = supply chain vasectomy.[[3]](https://www.investors.com/news/technology/aaoi-stock-applied-optoelectronics-earnings-aaoi-news-q42025) --- ## 2) FIGS (FIGS): “Healthcare apparel cash cow” vs “Promo pressure piñata” **Why it’s loud** **FIGS** ripped **+25%** to **$15.58** (4-year highs), Q4 beat + FY guide hike: rev **+10-12%**, EBITDA margins **12.8%** (up from 11.8%). Barclays flips to **Strong Buy**, volume exploding on short squeeze vibes. YTD **+32%**, but healthcare apparel? Meme medwear madness.[[6]](https://www.fool.com/investing/2026/02/27/why-figs-stock-is-up-today)[[7]](https://finviz.com/news/325978/figs-inc-figs-soars-to-4-year-high-as-analyst-turns-bullish) **Bull case (scrubs squeeze supernova)** Past supply chain/tariff/promos crushed margins—now fixed, direct-to-consumer flywheel + international expansion printing FCF. "Massive earnings beat ignites squeeze," analysts creaming on sticky nurse loyalty.[[6]](https://www.fool.com/investing/2026/02/27/why-figs-stock-is-up-today)[[8]](https://www.trefis.com/data/companies/FIGS/no-login-required/PuRngjli/FIGS-Stock-24-Massive-Earnings-Beat-and-Raised-Guidance-Ignites-Squeeze) **Bear case (cycle clownshow)** Healthcare spending squeeze + Amazon knockoffs erode pricing power, elevated promos signal demand wobbles. Tiny moat in commoditized threads, beta amplifies every recession fart.[[9]](https://www.investing.com/news/stock-market-news/wall-street-bullish-on-figs-inc-after-fourthquarter-results-4532526) **My take, first principles (brand cult vs commoditization cockblock)** Boil it: FIGS owns "cool scrubs" network effects (UGC + 95% retention = Lululemon for docs), margins inflect on DTC scale. Bears chase macro med cuts; bulls ride aging pop boom. Accum sub-$14, **$18/$22 calls** on Q1 international beats. Collar promo prostate. Risk: GLP-1 weight loss = fewer fat nurses? Nah, volume wins.[[6]](https://www.fool.com/investing/2026/02/27/why-figs-stock-is-up-today) --- ## 3) Novavax (NVAX): “Vax profit phoenix” vs “Guidance gutpunch” **Why it’s loud** **NVAX** blasted **+24%** to **$11.14** (52-wk high, YTD **+56%**), Q4 rev **$147M** (+67% YoY), EPS **$0.11** profit (beat loss est **-$0.49**). Swung FY profit **$440M** on **$1.12B** rev via Sanofi/Pfizer deals. But **32% short interest**, 2026 guide **$230-270M** < expectations **$381M**.[[2]](https://finance.yahoo.com/news/why-novavax-nvax-stock-soaring-180433998.html)[[10]](https://www.gurufocus.com/news/8658518/novavax-nvax-stock-surges-after-reporting-strong-q4-and-2025-financial-results) **Bull case (combo vax cash tsunami)** Sanofi milestones + Pfizer Matrix-M combo (flu-COVID) = post-pandemic pipeline pop. "Partnership-fueled profitability," shorts covering as BTC-like volatility squeezes.[[11]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nvax/novavax/news/why-novavax-nvax-is-up-102-after-partnership-fueled-return-t)[[12]](https://www.stocktitan.net/sec-filings/NVAX/8-k-novavax-inc-reports-material-event-978c94f9e9af.html) **Bear case (revenue revenue cliff)** 2026 guide tanks on COVID fade, execution risks galore (53 moves >5% last yr). High short = fraud ghosts linger, dilution dependency.[[10]](https://www.gurufocus.com/news/8658518/novavax-nvax-stock-surges-after-reporting-strong-q4-and-2025-financial-results) **My take, first principles (protein platform purity vs demand dryheave)** Strip naked: NVAX's protein tech > mRNA stability (Sanofi combo trials = $T potential), shorts ignore milestone waterfalls. Guide conservative AF for derisk. Long sub-$10, **$15 calls** on trial data—**partial collar** short squeeze. Risk: Flu season flop = biotech graveyard.[[2]](https://finance.yahoo.com/news/why-novavax-nvax-stock-soaring-180433998.html) --- ## Tape-Side Tactics (size your nuts or get neutered) - **AAOI**: Dip-buy **$70-75**; **$90C/$110C spreads** post-dilution noise.[[3]](https://www.investors.com/news/technology/aaoi-stock-applied-optoelectronics-earnings-aaoi-news-q42025) - **FIGS**: Accum **$14**; OTM **$18C** on squeeze momentum, puts if promos spike.[[6]](https://www.fool.com/investing/2026/02/27/why-figs-stock-is-up-today) - **NVAX**: **$9-10** entry; bull calls **$15+** with collars vs guide revisions.[[2]](https://finance.yahoo.com/news/why-novavax-nvax-stock-soaring-180433998.html) Not advice—Wall St's a glory hole grenade. DYOR, or kiss your sack goodbye.